Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
News|Articles|December 1, 2012
Aubagio (Teriflunomide)
New molecular entity: FDA approved teriflunomide (Aubagio, Genzyme, a Sanofi-Aventis company), a pyrimidine synthesis inhibitor, for the treatment of patients with relapsing forms of multiple sclerosis (MS).
Advertisement
Advertisement
Related to this article
Women face more gaps in healthcare than men, from missed screenings, undertreatment and biased coverage. PBMs are launching programs to address some of the gaps.
Navitus launched three modular options that let plan sponsors manage diabetes, weight, and lifestyle therapy access, cost, and outcomes with guaranteed ROI.
StarkRx has launched as a modular, cost-plus pharmacy benefit management company for self-funded employers using Judi Health’s PBM, Judi Rx, to administer claims.
National Alliance names Jenny Goins interim CEO after former leader’s arrest; details emerge on charges, firing timeline, and impact on healthcare policy circles.
Only 19% use AI predictive models in cancer care despite strong belief in impact; 2026 Oncology Care Index highlights reimbursement, training, funding barriers.
Hispanic HIV incidence rose 16.8% in antisanctuary counties after the 2018 public charge announcement, relative to baseline counties, a new study found.
A review of randomized clinical trials, nonrandomized trials and case reports suggests that the inflammatory bowel disease risk from treatment with IL-17 inhibitors is low.
Advertisement
Advertisement